Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Bone Marrow Transplant ; 48(7): 947-52, 2013 Jul.
Article de Anglais | MEDLINE | ID: mdl-23334272

RÉSUMÉ

Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8 ± 9.6% and 59.2 ± 9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.


Sujet(s)
Neuroblastome/mortalité , Neuroblastome/thérapie , Transplantation de cellules souches de sang périphérique , Conditionnement pour greffe/méthodes , Autogreffes , Femelle , Humains , Nourrisson , Nouveau-né , Mâle , Projets pilotes , Conditionnement pour greffe/effets indésirables , Maladies virales/étiologie , Maladies virales/mortalité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE